Insider Selling: Billiontoone (NASDAQ:BLLN) CTO Sells $1,000,000.00 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) CTO David Tsao sold 10,000 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $100.00, for a total transaction of $1,000,000.00. Following the completion of the transaction, the chief technology officer owned 1,000 shares in the company, valued at approximately $100,000. This represents a 90.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Tsao also recently made the following trade(s):

• On Monday, August 10th, David Tsao sold 10,000 shares of Billiontoone stock. The stock was sold at an average price of $92.86, for a total transaction of $928,600.00.
• On Monday, June 15th, David Tsao sold 20,000 shares of Billiontoone stock. The stock was sold at an average price of $102.27, for a total transaction of $2,045,400.00.

Billiontoone Stock Performance

Shares of BLLN stock opened at $93.24 on Friday. Billiontoone, Inc. has a 52 week low of $61.96 and a 52 week high of $150.44. The company has a market capitalization of $4.40 billion and a price-to-earnings ratio of 133.20. The company has a 50-day simple moving average of $115.10 and a 200 day simple moving average of $95.27. The company has a debt-to-equity ratio of 0.17, a quick ratio of 11.31 and a current ratio of 11.69.

Billiontoone (NASDAQ:BLLN) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share for the quarter, meeting the consensus estimate of $0.15. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. The firm had revenue of $109.45 million for the quarter. On average, sell-side analysts predict that Billiontoone, Inc. will post 0.83 earnings per share for the current year.

Hedge Funds Weigh In On Billiontoone

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BLLN. Rossby Financial LCC acquired a new stake in shares of Billiontoone during the 4th quarter worth $25,000. Wells Fargo & Company MN acquired a new position in Billiontoone in the fourth quarter valued at about $76,000. Smartleaf Asset Management LLC bought a new stake in Billiontoone during the fourth quarter worth about $80,000. Nano Cap New Millennium Growth Fund L P bought a new stake in Billiontoone during the fourth quarter worth about $82,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Billiontoone during the fourth quarter worth about $230,000.

Analysts Set New Price Targets

BLLN has been the topic of a number of research reports. JPMorgan Chase & Co. decreased their price objective on Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a report on Thursday, August 6th. BTIG Research reduced their target price on shares of Billiontoone from $142.00 to $130.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Wall Street Zen downgraded shares of Billiontoone from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings raised shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Finally, Guggenheim assumed coverage on shares of Billiontoone in a research note on Monday, June 29th. They issued a “buy” rating and a $125.00 price objective for the company. Six equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $126.71.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.